Financhill
Buy
81

PDEX Quote, Financials, Valuation and Earnings

Last price:
$48.87
Seasonality move :
1.86%
Day range:
$46.46 - $50.00
52-week range:
$16.84 - $59.60
Dividend yield:
0%
P/E ratio:
24.83x
P/S ratio:
2.77x
P/B ratio:
5.09x
Volume:
58.7K
Avg. volume:
37.1K
1-year change:
185.4%
Market cap:
$161.9M
Revenue:
$53.8M
EPS (TTM):
$2.00

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PDEX
Pro-Dex
$13.8M $0.38 23.84% 147.37% $54.00
CATX
Perspective Therapeutics
$267.3K -$0.25 -- -41.72% $15.58
VNRX
VolitionRX
$545.3K -$0.05 123.53% -51.52% $3.37
VTAK
Catheter Precision
$280K -$0.20 118.75% -11.57% --
WST
West Pharmaceutical Services
$740.9M $1.73 -1.45% -21.05% $286.12
XTNT
Xtant Medical Holdings
$31.8M -$0.02 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PDEX
Pro-Dex
$49.66 $54.00 $161.9M 24.83x $0.00 0% 2.77x
CATX
Perspective Therapeutics
$2.59 $15.58 $175.1M -- $0.00 0% 13.99x
VNRX
VolitionRX
$0.56 $3.37 $52M -- $0.00 0% 36.22x
VTAK
Catheter Precision
$0.38 -- $3.1M 0.44x $0.00 0% 1.03x
WST
West Pharmaceutical Services
$230.11 $286.12 $16.6B 34.40x $0.21 0.36% 5.86x
XTNT
Xtant Medical Holdings
$0.48 $1.75 $66.8M -- $0.00 0% 0.55x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PDEX
Pro-Dex
33.99% 3.333 10.75% 1.35x
CATX
Perspective Therapeutics
-- -3.661 -- --
VNRX
VolitionRX
-28.76% -0.785 8.83% 0.19x
VTAK
Catheter Precision
12% -2.395 128.21% 0.53x
WST
West Pharmaceutical Services
7.02% 1.553 0.92% 1.88x
XTNT
Xtant Medical Holdings
44.29% 0.232 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PDEX
Pro-Dex
$5.1M $2.7M 15.21% 21.59% 16.61% -$4.7M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
WST
West Pharmaceutical Services
$273.6M $169.8M 16.88% 18.15% 21.92% $85.2M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Pro-Dex vs. Competitors

  • Which has Higher Returns PDEX or CATX?

    Perspective Therapeutics has a net margin of 12.15% compared to Pro-Dex's net margin of --. Pro-Dex's return on equity of 21.59% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About PDEX or CATX?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than Pro-Dex, analysts believe Perspective Therapeutics is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is PDEX or CATX More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock PDEX or CATX?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or CATX?

    Pro-Dex quarterly revenues are $16.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Pro-Dex's net income of $2M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    CATX
    Perspective Therapeutics
    13.99x -- -- -$15.1M
  • Which has Higher Returns PDEX or VNRX?

    VolitionRX has a net margin of 12.15% compared to Pro-Dex's net margin of -1226.82%. Pro-Dex's return on equity of 21.59% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About PDEX or VNRX?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 501.2%. Given that VolitionRX has higher upside potential than Pro-Dex, analysts believe VolitionRX is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    VNRX
    VolitionRX
    2 1 0
  • Is PDEX or VNRX More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

  • Which is a Better Dividend Stock PDEX or VNRX?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or VNRX?

    Pro-Dex quarterly revenues are $16.8M, which are larger than VolitionRX quarterly revenues of $474.5K. Pro-Dex's net income of $2M is higher than VolitionRX's net income of -$5.8M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 36.22x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    VNRX
    VolitionRX
    36.22x -- $474.5K -$5.8M
  • Which has Higher Returns PDEX or VTAK?

    Catheter Precision has a net margin of 12.15% compared to Pro-Dex's net margin of -4291.67%. Pro-Dex's return on equity of 21.59% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About PDEX or VTAK?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 419.62%. Given that Catheter Precision has higher upside potential than Pro-Dex, analysts believe Catheter Precision is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is PDEX or VTAK More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

  • Which is a Better Dividend Stock PDEX or VTAK?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or VTAK?

    Pro-Dex quarterly revenues are $16.8M, which are larger than Catheter Precision quarterly revenues of $96K. Pro-Dex's net income of $2M is higher than Catheter Precision's net income of -$4.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while Catheter Precision's PE ratio is 0.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 1.03x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    VTAK
    Catheter Precision
    1.03x 0.44x $96K -$4.1M
  • Which has Higher Returns PDEX or WST?

    West Pharmaceutical Services has a net margin of 12.15% compared to Pro-Dex's net margin of 17.38%. Pro-Dex's return on equity of 21.59% beat West Pharmaceutical Services's return on equity of 18.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
  • What do Analysts Say About PDEX or WST?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand West Pharmaceutical Services has an analysts' consensus of $286.12 which suggests that it could grow by 24.34%. Given that West Pharmaceutical Services has higher upside potential than Pro-Dex, analysts believe West Pharmaceutical Services is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    WST
    West Pharmaceutical Services
    7 2 0
  • Is PDEX or WST More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

  • Which is a Better Dividend Stock PDEX or WST?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.36% to investors and pays a quarterly dividend of $0.21 per share. Pro-Dex pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PDEX or WST?

    Pro-Dex quarterly revenues are $16.8M, which are smaller than West Pharmaceutical Services quarterly revenues of $748.8M. Pro-Dex's net income of $2M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while West Pharmaceutical Services's PE ratio is 34.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 5.86x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    WST
    West Pharmaceutical Services
    5.86x 34.40x $748.8M $130.1M
  • Which has Higher Returns PDEX or XTNT?

    Xtant Medical Holdings has a net margin of 12.15% compared to Pro-Dex's net margin of -10.04%. Pro-Dex's return on equity of 21.59% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About PDEX or XTNT?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Xtant Medical Holdings has higher upside potential than Pro-Dex, analysts believe Xtant Medical Holdings is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is PDEX or XTNT More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

  • Which is a Better Dividend Stock PDEX or XTNT?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or XTNT?

    Pro-Dex quarterly revenues are $16.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Pro-Dex's net income of $2M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock